Legal Representation
Attorney
Jayme M. Torelli
USPTO Deadlines
Next Deadline
194 days remaining
Statement of Use Due - Extension 3 Granted
Due Date
February 13, 2026
Extension Available
Until February 13, 2025
Application History
20 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Jun 28, 2025 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Jun 27, 2025 | EX3G | S | SOU EXTENSION 3 GRANTED | Loading... |
| Jun 27, 2025 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Jun 27, 2025 | EXT3 | S | SOU EXTENSION 3 FILED | Loading... |
| Mar 4, 2025 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Jan 3, 2025 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
| Jan 3, 2025 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
| Jan 2, 2025 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Jun 17, 2024 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Jun 17, 2024 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Jun 17, 2024 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Jun 17, 2024 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Feb 13, 2024 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Dec 19, 2023 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Dec 19, 2023 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Nov 29, 2023 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Nov 16, 2023 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Nov 13, 2023 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Sep 18, 2023 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Aug 22, 2023 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders; Pharmaceutical preparations for the central nervous system; Pharmaceutical preparations for the prevention of motion sickness; Pharmaceutical preparations for the prevention of social anxiety or performance anxiety; Pharmaceutical preparations for the treatment and prevention of craving; Pharmaceutical preparations for the treatment and prevention of motion sickness; Pharmaceutical preparations for the treatment and prevention of insomnia; Pharmaceutical preparations for the treatment and prevention of social anxiety or performance anxiety; Pharmaceutical preparations for the treatment of circadian rhythm diseases and disorders; Pharmaceutical preparations for the treatment of Non-24-Hour Sleep-Wake Disorder; Pharmaceutical preparations for the treatment of jet lag disorder; Pharmaceutical preparations for the treatment of Delayed Sleep Phase Disorder (DSPD); Pharmaceutical preparations for the treatment of bipolar disorder; Pharmaceutical preparations for the treatment of schizophrenia; Pharmaceutical preparations for the treatment of atopic dermatitis; Pharmaceutical preparations for the treatment of pruritus; Pharmaceutical preparations for the treatment of gastroparesis; Pharmaceutical preparations for the treatment of motion sickness; Pharmaceutical preparations for the treatment of hematologic malignancies; Pharmaceutical preparations for the treatment of insomnia; Pharmaceutical preparations for the treatment of Autism Spectrum Disorder (ASD); Pharmaceutical preparations for the treatment of Parkinson's Disease Psychosis; Pharmaceutical preparations for the treatment of COVID-19 pneumonia; Pharmaceutical preparations for the treatment of social anxiety or performance anxiety; Pharmaceutical preparations for the treatment of Smith-Magenis Syndrome; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for use in dermatology
Classification
International Classes
005